[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632458":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":10,"id":37,"slug":10,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Adult patients with iTTP",null,"Patients with a confirmed diagnosis of iTTP, aged ≥ 18 years, treated with daratumumab for iTTP",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Juri A Giannotta, M.D.","CONTACT","+390255035273","juri.giannotta@policlinico.mi.it",[19],{"facility":20,"status":21,"city":22,"state":10,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Angelo Bianchi Bonomi Hemophilia and Thrombosis Center","RECRUITING","Milan","Italy","IT",{"type":26,"coordinates":27},"Point",[28,29],12.59836,42.78235,{"lat":29,"lon":28},[32,33],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"name":14,"role":34,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100632458",false,"NCT07513948","Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura","DarTTP: an Observational, International, Multicentric Study on Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)","DarTTP","Inclusion Criteria:\n\n* patients with a confirmed diagnosis of iTTP (i.e., ADAMTS13 activity \\\u003C10% with anti-ADAMTS13 antibodies detected);\n* aged ≥ 18 years;\n* male and female patients;\n* treated with daratumumab for iTTP.\n\nExclusion Criteria:\n\n* patients unwilling or unable to provide their informed consent;\n* follow-up \\\u003C 6 months after daratumumab administration.","ALL","18 Years","99 Years",{"count":48,"type":49},40,"ESTIMATED","OBSERVATIONAL","Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.",[53],"Thrombotic Thrombocytopenic Purpura, Acquired",[55,56,57],"daratumumab","thrombotic thrombocytopenic purpura","ADAMTS13","2026-04-13",{"date":60,"type":61},"2026-04-14","ACTUAL",{"date":63,"type":61},"2025-10-01",{"date":65,"type":49},"2026-08",{"name":5,"class":6},1]